These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 23159358)

  • 21. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study.
    Ebid AH; Ahmed MM; Mohammed SA
    Ther Drug Monit; 2007 Jun; 29(3):305-12. PubMed ID: 17529887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influenza immunization does not predominantly alter levels of phenytoin, and cytochrome P-450 enzymes in epileptic patients receiving phenytoin monotherapy.
    Soontornpun A; Manoyana N; Apaijai N; Pinyopornpanish K; Pinyopornpanish K; Nadsasarn A; Tanprawate S; Chattipakorn N; Chattipakorn SC
    Epilepsy Res; 2020 Nov; 167():106471. PubMed ID: 33007725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children.
    Suvichapanich S; Jittikoon J; Wichukchinda N; Kamchaisatian W; Visudtibhan A; Benjapopitak S; Nakornchai S; Manuyakorn W; Mahasirimongkol S
    J Hum Genet; 2015 Aug; 60(8):413-7. PubMed ID: 25994870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis.
    Chuang YC; Chuang HY; Lin TK; Chang CC; Lu CH; Chang WN; Chen SD; Tan TY; Huang CR; Chan SH
    Epilepsia; 2012 Jan; 53(1):120-8. PubMed ID: 22085257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity.
    Depondt C; Godard P; Espel RS; Da Cruz AL; Lienard P; Pandolfo M
    Eur J Neurol; 2011 Sep; 18(9):1159-64. PubMed ID: 21338443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
    Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
    Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of glucose homeostasis and lipid profile in adult, seizure-free, epileptic patients in Asian population.
    Phabphal K; Limapichat K; Sathirapanya P; Setthawatcharawanich S; Geater A
    Eur J Neurol; 2012 Sep; 19(9):1228-34. PubMed ID: 22494156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.
    Brandolese R; Scordo MG; Spina E; Gusella M; Padrini R
    Clin Pharmacol Ther; 2001 Oct; 70(4):391-4. PubMed ID: 11673755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
    Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
    Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction.
    Citerio G; Nobili A; Airoldi L; Pastorelli R; Patruno A
    Neurology; 2003 Apr; 60(8):1395-6. PubMed ID: 12707459
    [No Abstract]   [Full Text] [Related]  

  • 31. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
    Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
    Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.
    Franken CC; Kaiser AF; Krüger JC; Overbeck K; Mügge A; Neubauer H
    Thromb Haemost; 2013 Jul; 110(1):131-40. PubMed ID: 23615745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenytoin toxicity due to genetic polymorphism.
    McCluggage LK; Voils SA; Bullock MR
    Neurocrit Care; 2009; 10(2):222-4. PubMed ID: 19030785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of multi-dose activated charcoal in phenytoin toxicity secondary to genetic polymorphism.
    Chan BS; Sellors K; Chiew AL; Buckley NA
    Clin Toxicol (Phila); 2015 Feb; 53(2):131-3. PubMed ID: 25597548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics of acenocoumarol pharmacodynamics.
    Morin S; Bodin L; Loriot MA; Thijssen HH; Robert A; Strabach S; Verstuyft C; Tregouet DA; Dubert L; Laurent-Puig P; Funck-Brentano C; Jaillon P; Beaune PH; Becquemont L
    Clin Pharmacol Ther; 2004 May; 75(5):403-14. PubMed ID: 15116053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenytoin neurotoxicity in a child carrying new STXBP1 and CYP2C9 gene mutations.
    Guacci A; Chetta M; Rizzo F; Marchese G; De Filippo MR; Giurato G; Nassa G; Ravo M; Tarallo R; Rocco T; Operto FF; Weisz A; Coppola G
    Seizure; 2016 Jan; 34():26-8. PubMed ID: 26658169
    [No Abstract]   [Full Text] [Related]  

  • 38. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.
    Sachse-Seeboth C; Pfeil J; Sehrt D; Meineke I; Tzvetkov M; Bruns E; Poser W; Vormfelde SV; Brockmöller J
    Clin Pharmacol Ther; 2009 Mar; 85(3):273-6. PubMed ID: 19005461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.
    Prieto-Pérez R; Ochoa D; Cabaleiro T; Román M; Sánchez-Rojas SD; Talegón M; Abad-Santos F
    J Clin Pharmacol; 2013 Dec; 53(12):1261-7. PubMed ID: 23996211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
    Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.